[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355541-105":59,"doc-detail-355541-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prostate-cancer-and-car-t-therapy-a-systematic-review","Prostate cancer and CAR-T therapy - a systematic review","","Prostate cancer (PCa) remains a leading cause of cancer mortality in men, and metastatic castration-resistant prostate cancer (mCRPC) is especially difficult to treat. Immunotherapy and chimeric antigen receptor (CAR) T cells have transformed hematologic malignancies, but their role in prostate cancer is still being defined. This systematic review evaluated clinical trials from 2014–2024 under PRISMA to assess safety and early efficacy across different CAR-T targets and dosing strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prostate-cancer-and-car-t-therapy-a-systematic-review/355541/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prostate-cancer-and-car-t-therapy-a-systematic-review/355541.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which clinical trials were included in this systematic review of CAR-T therapy for prostate cancer?","Question",{"text":113,"@type":114},"The review included all published and registered clinical trials from 2014–2024 that involved CAR-T therapy in prostate cancer, screened under PRISMA-based inclusion/exclusion criteria.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What CAR-T targets and outcomes were most commonly evaluated for prostate cancer?",{"text":118,"@type":114},"Early-phase trials investigated CAR-T therapies targeting PSMA, PSCA, and other tumor-associated antigens such as CD70, GD2, and TGFβDN, reporting preliminary efficacy signals including PSA reductions and radiographic partial responses.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety and efficacy challenges limit CAR-T therapy in mCRPC according to the review?",{"text":122,"@type":114},"Safety concerns include cytokine release syndrome (often grade 1–2) and occasional neurotoxicity or fatal events at higher doses, while limitations include antigen escape and tumor microenvironment barriers that affect persistence and sustained efficacy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355541,1790463921,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","HakemZadeh etal. BMC Cancer (2026) 26:514 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15703-1](https://doi.org/10.1186/s12885-026-15703-1)  \nSYSTEMATIC REVIEW Open Access  \nProstate cancer and CAR-T therapy: a systematic review  \nFarigol Hakem Zadeh 1,2*, Nikita Shah 1,2 and Victoria Bird3  \nAbstract  \nImportance Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men globally, with castration-resistant prostate cancer (CRPC) representing a particularly challenging stage of disease. Despite therapeutic advances, including androgen receptor inhibitors (ARPIs), taxane-based chemotherapy, and radiopharmaceuticals, durable responses in metastatic CRPC (mCRPC) are limited.  \nObjective Immunotherapy, especially chimeric antigen receptor (CAR) T cell therapy, has revolutionized hematologic malignancies, yet its application in solid tumors like prostate cancer remains under investigation. We conducted a systematic review in accordance with PRISMA guidelines to evaluate all published and registered clinical trials (2014–2024) involving CAR-T therapy in prostate cancer.  \nEvidence review Databases searched included PubMed, [ClinicalTrials.gov](ClinicalTrials.gov), and Cochrane. Studies were screened using stringent inclusion/exclusion criteria and analyzed for trial phase, antigen targets, dosing, safety (cytokine release syndrome [CRS], neurotoxicity, dose-limiting toxicities [DLTs]), and early efficacy outcomes. Data extraction was performed independently by two reviewers with AI-assisted adjudication. Out of 32,565 records, 27 trials met inclusion, of which 8 had published outcomes.  \nFindings Eight early-phase trials investigated CAR-T therapies targeting PSMA, PSCA, and other tumor-associated antigens (e. g., CD70, GD2, TGFβDN) . PSMA-directed CAR-T trials showed variable safety and preliminary efficacy, with some reporting PSA reductions > 50% and radiographic partial responses. CRS (Grade 1–2) occurred in up to 100% of patients, with isolated cases of neurotoxicity and fatal adverse events in higher-dose cohorts. Trials employing armored CARs (e. g., TGFβDN, iCasp9 switches) demonstrated improved persistence and early anti-tumor activity. The use of dual-target CARs and gene-editing strategies (e. g., piggyBac transposons, PD-1 knockouts) reflect the field’s evolving precision.  \nConclusions and relevance CAR-T therapy in prostate cancer, particularly mCRPC, is a promising yet nascent  \nfield marked by heterogeneous safety profiles and early signs of efficacy. PSMA remains the most validated target, though antigen escape and tumor microenvironment barriers continue to limit success. Innovative constructs and combinatorial strategies may enhance clinical outcomes. Continued trial development and refinement are critical to unlocking CAR-T’s potential in solid tumors.  \n*Correspondence:  \nFarigol Hakem Zadeh [Farigol.HakemZadeh@hcahealthcare.com](Farigol.HakemZadeh@hcahealthcare.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view ","cbCailZoQA1Lc0aw","https://ap.wps.com/l/cbCailZoQA1Lc0aw","pdf",1839971,"English","# Abstract\n## Importance\n## Objective\n## Evidence review\n## Findings\n## Conclusions and relevance\n# Key Points\n## Question\n## Findings\n## Meaning\n# Introduction","[{\"question\":\"Which clinical trials were included in this systematic review of CAR-T therapy for prostate cancer?\",\"answer\":\"The review included all published and registered clinical trials from 2014–2024 that involved CAR-T therapy in prostate cancer, screened under PRISMA-based inclusion/exclusion criteria.\"},{\"question\":\"What CAR-T targets and outcomes were most commonly evaluated for prostate cancer?\",\"answer\":\"Early-phase trials investigated CAR-T therapies targeting PSMA, PSCA, and other tumor-associated antigens such as CD70, GD2, and TGFβDN, reporting preliminary efficacy signals including PSA reductions and radiographic partial responses.\"},{\"question\":\"What safety and efficacy challenges limit CAR-T therapy in mCRPC according to the review?\",\"answer\":\"Safety concerns include cytokine release syndrome (often grade 1–2) and occasional neurotoxicity or fatal events at higher doses, while limitations include antigen escape and tumor microenvironment barriers that affect persistence and sustained efficacy.\"}]","Prostate cancer and CAR-T therapy - a systematic review | PDF",1790119740,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/136d2934202f916ec5b77685100b314e.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7393c1837008c26b9593106395eca6bc.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59ff1378930a62625e54f867b7d6409c.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdc3d2561214f75c3c4d4ca6dec4d1b2.webp",980,1306]